Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Revenue from Comirnaty, its COVID vaccine, has fallen by 66% this year. But in specialty care, revenue has risen by 11%, and in oncology, the company received a boost from drugs it acquired from ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Schools closed. Hospitals overflowed. Around the world, millions died. For Pfizer, the success of its Comirnaty vaccine and its antiviral drug Paxlovid couldn’t have come at a better time.